atezolizumab + bevacizumab + chemotherapy

**Atezolizumab + bevacizumab + chemotherapy** is a triple combination regimen used primarily to treat advanced cancers, notably metastatic non-squamous non-small cell lung cancer (NSCLC) and metastatic triple-negative breast cancer (aTNBC)[7][3]. - **Atezolizumab** is a monoclonal antibody checkpoint inhibitor targeting PD-L1. By blocking the PD-L1 protein on tumor cells, it prevents the suppression of the immune response, allowing cytotoxic T cells to attack cancer cells[5]. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of new blood vessels), thus starving the tumor of nutrients and oxygen needed for growth[5][6]. - **Chemotherapy** agents (commonly paclitaxel and carboplatin in NSCLC; paclitaxel in breast cancer regimens) act by disrupting cell division and inducing cytotoxicity in rapidly dividing cells. This regimen is approved in several indications as a first-line treatment for metastatic cancers, with improved overall survival and progression-free survival over standard therapies[7][3].

Other names

atezolizumab + bevacizumab + chemotherapy